NPHLA Tracker · Clinical trials (ClinicalTrials.gov)
Clinical Trial Tracker: Metabolic & Aesthetic Medicine
Clinical trials followed in metabolic and aesthetic medicine — obesity and incretin therapies, neurotoxins, dermal fillers, regenerative treatments and hair restoration — with each study’s status, phase and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 195
- Changed in 7 days
- 0
- Latest record
- Jurisdiction
- International / multiple
Records
195 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908Conditions: Polycystic Ovary. Interventions: liraglutide; Metformin | Completed | Phase 3 | Beni-Suef University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05965908 (opens in a new tab)Primary source | System checked NPHLA updated |
| MMP US P3 416: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle ProminenceNCT06387394Conditions: Masseter Muscle Prominence. Interventions: BOTOX; Placebo | Completed | Phase 3 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06387394 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06672939 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066Conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea. Interventions: Retatrutide; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05929066 (opens in a new tab)Primary source | System checked NPHLA updated |
| Microneedling for Androgenic Alopecia: a Clinical StudyNCT07580521Conditions: Androgenic Alopecia. Interventions: Microneedling monotherapy without drugs | Active, not recruiting | Not applicable | Taipei Medical University WanFang Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07580521 (opens in a new tab)Primary source | System checked NPHLA updated |
| EXO-MINO: Exosome Injection Versus Topical Minoxidil for Androgenetic AlopeciaNCT07776015Conditions: Androgenetic Alopecia; Exosomes. Interventions: exosomes injection; Topical Minoxidil 5% | Completed | Not applicable | Tanta University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07776015 (opens in a new tab)Primary source | System checked NPHLA updated |
| PROBIO-GLP1: Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA TreatmentNCT07213323Conditions: Obesity &Amp; Overweight; Digestive Disorders. Interventions: Probiotics (Natural product); Placebo | Recruiting | Not applicable | Hospices Civils de Lyon | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07213323 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-1: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903Conditions: Obesity; Overweight; Overweight or Obesity. Interventions: Orforglipron; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05869903 (opens in a new tab)Primary source | System checked NPHLA updated |
| Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar RhytidesNCT06448676Conditions: Wrinkle; Glabellar Frown Lines; Glabellar Furrowing. Interventions: Botulinum toxin type A | Recruiting | Phase 4 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06448676 (opens in a new tab)Primary source | System checked NPHLA updated |
| CER-4-T2D: Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917Conditions: Cardiovascular Events; Type2 Diabetes; Renal Disease. Interventions: SGLT2 inhibitor; DPP-4 inhibitor; GLP-1RA; 2nd generation SU | Active, not recruiting | Phase not stated | Brigham and Women's Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05220917 (opens in a new tab)Primary source | System checked NPHLA updated |
| ZQL007: Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)NCT03883412Conditions: Type2 Diabetes. Interventions: Exercise; Liraglutide | Recruiting | Phase 4 | University of Virginia | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT03883412 (opens in a new tab)Primary source | System checked NPHLA updated |
| Assessing the Impact of Botulinum Toxin Type A on Facial Wrinkles: A Comprehensive Clinical InvestigationNCT06385171Conditions: Wrinkle. Interventions: Botulinum toxin type A | Withdrawn | Phase not stated | Global Aesthetics LLC | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06385171 (opens in a new tab)Primary source | System checked NPHLA updated |
| MMP US P3 417: A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult ParticipantsNCT06399718Conditions: Masseter Muscle Prominence. Interventions: BOTOX; Placebo | Completed | Phase 3 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06399718 (opens in a new tab)Primary source | System checked NPHLA updated |
| Pre-approval Expanded Access of Retatrutide (LY3437943)NCT07629401Conditions: Obesity; Obesity-related Complications. Interventions: Retatrutide | available | Phase not stated | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07629401 (opens in a new tab)Primary source | System checked NPHLA updated |
| LIGHT-MCI: LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529Conditions: Type 2 Diabetes Mellitus; Mild Cognitive Impairment. Interventions: Liraglutide; Empagliflozin; Linagliptin | Completed | Not applicable | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05313529 (opens in a new tab)Primary source | System checked NPHLA updated |
| FLAMES: Fibrosis Lessens After Metabolic SurgeryNCT06374875Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD); Non-Alcoholic Fatty Liver Disease; Metabolic Dysfunction-Associated Steat…. Interventions: Metabolic surgery; Incretin-Based Therapy | Recruiting | Phase 4 | The Cleveland Clinic | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06374875 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 DiabetesNCT06993792Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06993792 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-2: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079Conditions: Type 2 Diabetes; Obesity; Overweight; Obstructive Sleep Apnea. Interventions: Retatrutide; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05929079 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-3: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045Conditions: Obesity; Cardiovascular Diseases. Interventions: Retatrutide; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05882045 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related ComorbidityNCT06972459Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06972459 (opens in a new tab)Primary source | System checked NPHLA updated |
| Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy DiscontinuationNCT07729332Conditions: Obesity. Interventions: Phentermine Pill; Orforglipron | Not yet recruiting | Phase 4 | Massachusetts General Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07729332 (opens in a new tab)Primary source | System checked NPHLA updated |
| Zinc Supplementation Prior to Botox Injections for Spasmodic DysphoniaNCT05892770Conditions: Spasmodic Dysphonia. Interventions: Zinc gluconate supplement; Botulinum toxin type A | Completed | Phase 1 / Phase 2 | University of Florida | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05892770 (opens in a new tab)Primary source | System checked NPHLA updated |
| Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor AgonistsNCT07702461Conditions: Obesity & Overweight; Diabetes (DM). Interventions: Glucagon-Like Peptide-1 Agonist (GLP-1) | Recruiting | Phase not stated | Ohio State University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07702461 (opens in a new tab)Primary source | System checked NPHLA updated |
| Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816Conditions: Obesity. Interventions: Liraglutide; Oral Semaglutide; Semaglutide | Recruiting | Phase 1 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07225816 (opens in a new tab)Primary source | System checked NPHLA updated |
| Botulinum Toxin Type A Versus Cross-Linked Hyaluronic Acid Filler Myomodulation for Non-Surgical Management of Excessive Gingival DisplayNCT07715331Conditions: Excessive Gingival Display; Gingival Diseases; Gummy Smile; Esthetics, Dental. Interventions: Botulinum Toxin Type A (Refinex®); Cross-Linked Hyaluronic Acid Filler (Juvéderm Voluma® with Lidocaine) | Completed | Not applicable | Al-Azhar University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07715331 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603Conditions: Type 2 Diabetes. Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06297603 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-5: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383Conditions: Obesity. Interventions: Retatrutide; Tirzepatide | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06662383 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes MellitusNCT06982859Conditions: Diabetes Mellitus; Insulin Sensitivity. Interventions: Retatrutide; Semaglutide; Placebo | Active, not recruiting | Phase 1 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06982859 (opens in a new tab)Primary source | System checked NPHLA updated |
| SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityNCT04775082Conditions: Obesity. Interventions: Liraglutide; Placebo | Active, not recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04775082 (opens in a new tab)Primary source | System checked NPHLA updated |
| Botulinum Toxin Type A Injection Sites for Oral Commissure PtosisNCT07646886Conditions: Facial Aging; Melomental Folds; Oral Commissure Ptosis. Interventions: OnabotulinumtoxinA (Upper Depressor Anguli Oris Injection); OnabotulinumtoxinA (Lower Depressor Anguli Oris Injection) | Not yet recruiting | Phase 4 | Peking University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07646886 (opens in a new tab)Primary source | System checked NPHLA updated |
| GLP1-AD-TTE: GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial EmulationNCT07677865Conditions: Alzheimer Disease; Diabetes Mellitus Type 2; Obesity & Overweight. Interventions: GLP-1 Receptor Agonists; DPP-4 Inhibitors | Completed | Phase not stated | West China Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07677865 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to HypoglycemiaNCT06982846Conditions: Type 2 Diabetes Mellitus. Interventions: Retatrutide; Placebo | Completed | Phase 1 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06982846 (opens in a new tab)Primary source | System checked NPHLA updated |
| Estimating the Impact of Obesity Medications on Clinical and Economic OutcomesNCT07640139Conditions: Obesity. Interventions: Incretin-based therapies (GLP-1 and GLP-1/GIP) | Enrolling by invitation | Phase not stated | Indiana University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07640139 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-9: A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415Conditions: Obesity; Overweight. Interventions: Retatrutide | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07357415 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaNCT07107334Conditions: Endometrioid Endometrial Adenocarcinoma. Interventions: Glucagon-like peptide 1 receptor agonist | Recruiting | Phase 2 | University of Florida | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07107334 (opens in a new tab)Primary source | System checked NPHLA updated |
| GLICH: GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized TrialNCT07613437Conditions: Intracerebral Hemorrhage. Interventions: Semaglutide, 0.5 mg/mL | Not yet recruiting | Phase 2 | Chinese University of Hong Kong | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07613437 (opens in a new tab)Primary source | System checked NPHLA updated |
| Use of Liraglutide in Children Aged 6 to 12 Years With Severe ObesityNCT07590219Conditions: Severe Obesity; Cardiovascular Function; Liraglutide; Childhood Obesity; Echocardiography; Speckle Tracking. Interventions: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml | Active, not recruiting | Phase 4 | University of Sao Paulo General Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07590219 (opens in a new tab)Primary source | System checked NPHLA updated |
| ZQL008: Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic SyndromeNCT04575844Conditions: Metabolic Syndrome. Interventions: Liraglutide; Exercise training; Liraglutide + Exercise training | Recruiting | Phase 4 | University of Virginia | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04575844 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-8: A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719Conditions: Obesity; Overweight. Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07232719 (opens in a new tab)Primary source | System checked NPHLA updated |
| GZBF: Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are OverweightNCT07467447Conditions: Obesity. Interventions: Retatrutide (LY3437943); Placebo; Standardized diet and physical activity counseling throughout the study. | Recruiting | Phase 2 | Hudson Biotech | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07467447 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660Conditions: Diabetes Type 2. Interventions: Retatrutide; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06354660 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-6: A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268Conditions: Obesity. Interventions: Retatrutide; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06859268 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-4: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367Conditions: Obesity; Overweight; Osteo Arthritis Knee. Interventions: Retatrutide; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05931367 (opens in a new tab)Primary source | System checked NPHLA updated |
| BICEP: Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist TreatmentNCT07226947Conditions: Obesity; Body Composition. Interventions: Smartwatch activity and body composition monitor; General guidance on recommended exercise | Recruiting | Not applicable | Massachusetts General Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07226947 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151Conditions: Overweight or Obesity; CKD; Type 2 Diabetes. Interventions: Retatrutide; Placebo | Completed | Phase 2 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05936151 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) for two broad searches — obesity and incretin therapies, and aesthetic and regenerative medicine (botulinum toxin, dermal fillers, polynucleotides, exosomes, platelet-rich plasma) — and for every topic with a trial query, on the schedule set in the Source Registry. Each study is stored with its registry fields as published. Changes in overall status and newly posted results are recorded with the date the pipeline detected them.
This tracker lists every tracked study whose last registry update falls within the past 365 days, newest first. Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch dated within the last 365 days.
What does it cover?
Studies on ClinicalTrials.gov — from the United States and other countries — that match the configured searches, from the date tracking began. Studies registered elsewhere, described with other terms, or not updated in the last year are not included.
What are its limitations?
Registry data is supplied by sponsors and may be incomplete or out of date. Inclusion reflects search terms, not clinical importance. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.